R-I will not be challenged in Europe..R-I is one of the best run CVOT ever..There is no patent challenge in Europe...
Hikma and Reddi have not won the R-I CVOT indication..They no doubt might try to shoe horn their way into the the R-I indication..But one thing Du did say was that if the generics attempt to sell Vascepa for the CVD reduction that they would be guilty of indirect infringement by inducement..That is encouraging physicians to use the generic for the R-I indication..
PS the generics were not happy about that...We shall see where this goes as we have socialist dems who think everyone needs free health care and nobody should make a dollar by forwarding medical science...This of course is simply a ruse to get votes so they can feed off the country. Don't worry about Amarin...You need to worry about America...
News 
Market Data 
Discover 
